FDA Grants Priority Review to UGN-101 for Urothelial Cancer
The FDA has granted a priority review designation to a new drug application for UGN-101 for the treatment of patients with low-grade, upper tract urothelial cancer.
Related Articles
Tucatinib/Trastuzumab Yields Durable Responses in HER2-Mutated Metastatic Breast Cancer
Final analysis of SGNTUC-019 showed a 41.9% ORR, an 80.6% DCR, and a 18.2-month DOR with tucatinib/trastuzumab in pretreated, HER2-mutated metastatic breast cancer.
Defining Resectability in Stage III NSCLC: Addressing Key Controversies
Panelists discuss how the resectability of stage III non-small cell lung cancer tumors remains controversial, particularly regarding the role of surgery in multi-station N2 disease…
Hematology Experts Outline the Top Abstracts to Watch at the 2025 ASCO Annual Meeting
Oncology experts detail their most highly-anticipated hematology abstracts and data to watch at the upcoming 2025 ASCO Annual Meeting.
CHMP Recommends EU Approval of Zanidatamab for HER2+ Advanced Biliary Tract Cancer
The EMA’s CHMP issued a positive opinion for zanidatamab in previously treated HER2-positive biliary tract cancer.
Neoadjuvant Niraparib Fails to Produce Substantial Pathologic Responses After Radical Prostatectomy in DDR-Deficient Prostate Cancer
No complete or partial pathologic responses were achieved with neoadjuvant niraparib in patients with DDR-deficient prostate cancer following surgery.
Cretostimogene Grenadenorepvec Produces Durable CRs in High-Risk BCG-Unresponsive NMIBC
Cretostimogene grenadenorepvec generated complete responses in patients with high-risk BCG-unresponsive NMIBC and CIS with or without Ta/T1 tumors.
TAR-200 Yields Prolonged DFS in BCG-Unresponsive, Papillary High-Risk NMIBC
TAR-200 produced durable disease-free survival in BCG-unresponsive, papillary-only, high-risk non–muscle-invasive bladder cancer.
Sasanlimab Plus BCG Improves EFS in High-Risk NMIBC
Sasanlimab plus BCG significantly improved EFS vs BCG alone in high-risk non–muscle-invasive bladder cancer.
CHMP Recommends Brentuximab Vedotin Plus ECADD for Newly Diagnosed Stage IIB/III/IV Hodgkin Lymphoma
The EMA’s CHMP has recommended the approval of brentuximab vedotin plus ECADD for newly diagnosed, stage IIB/III/IV Hodgkin lymphoma.
Disease Reassessment at First Progression and Treatment Options for Resistance Mechanisms in EGFR-mutant NSCLC
Panelists discuss how subsequent therapy after initial disease progression should consider patient symptomatology, biomarker testing through tissue or liquid biopsies, and potential treatment options including…